Richard Baffour

TL;DR: Bone marrow cells secrete angiogenic factors that induce endothelial cell proliferation and, when injected transendocardially, augment collateral perfusion and myocardial function in ischemic myocardium.

TL;DR: Preliminary clinical data indicates feasibility of catheter-based transendocardial delivery of ABM to ischemic myocardium in patients with severe symptomatic chronic myocardial ischemia not amenable to conventional revascularization.

TL;DR: Quantitative coronary analysis indicates that percentage area stenosis and percentage diameter stenosis in magnesium alloy stent segments improved significantly at 3 months as compared to 28 days; however, reduced neointima did not result in larger lumen.

TL;DR: The current study demonstrates that stents made of biocorrodible iron are safe and in some of the measured parameters, such as intimal thickness, intimal area, and percentage occlusion, there was a trend in favor of the iron stents.

TL;DR: There is ample experimental evidence justifying an optimistic outlook relating to the eventually being successful in enhancing collateral flow to ischemic tissue in a clinical setting, and an optimal angiogenesis intervention may require a 'multiple factor' strategy.